EGFR and cancer: Interestingly, combination with osimertinib enhanced the efficacy of JBJ-04-125-02 (6) and improved the targeting of JBJ-04-125-02 (6) to cancer cells [98], indicating that the combined use of covalent mutant-selective ATP-competitive inhibitors and EGFR allosteric inhibitors may be an effective treatment strategy for patients with EGFR-mutant disease (Fig. 5).